Nancy Maureen Hardy MD FACP

Oncology•Baltimore, MD

Associate Professor, Medicine, Greenebaum Cancer Center

Join to View Full Profile

22 S Greene StBaltimore, MD 21201
Phone+1 410-328-6841
Fax+1 410-328-6841

Education & Training

National Cancer InstituteFellowship, Stem Cell Transplantation and Immunotherapy, 2003 - 2006
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1999 - 2003
Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
Duke University HospitalResidency, Internal Medicine, 1995 - 1998
University of Washington School of MedicineClass of 1995

Certifications & Licensure

MD State Medical License 2004 - 2026
WA State Medical License 2010 - 2026
NC State Medical License 1998 - 2022
DC State Medical License 2013 - 2014

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Start of enrollment: 2010 Dec 10
RECRUITING
PHASE2
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Mar 30
Terminated
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Start of enrollment: 2015 Nov 01
Completed
Phase 1
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation Start of enrollment: 2017 Feb 08
Completed
Phase 1
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2017 Jul 19
Completed
Phase 3
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) Start of enrollment: 2018 Mar 23
ACTIVE_NOT_RECRUITING
PHASE3
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease Start of enrollment: 2018 Feb 27
Terminated
Phase 1
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
RECRUITING
PHASE2
Roles: Contact
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU Start of enrollment: 2024 May 15
RECRUITING
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.
Djordje Atanackovic, Tim Luetkens, Dina Schneider, Peirong Hu, Xu Wang
Nature Communications. 2025-07-04
1 citations
CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant.
David T Chen, Olga Goloubeva, Aaron P Rapoport, Saurabh Dahiya, Djordje Atanackovic
Clinical Lymphoma, Myeloma & Leukemia. 2025-06-01
Successful treatment of refractory cold agglutinin syndrome using fixed duration daratumumab, bortezomib and dexamethasone with a sutimlimab bridge.
Brad Rybinski, Miranda James, Nancy Hardy, Rima Koka, Aaron P Rapoport
Haematologica. 2025-05-22

Abstracts/Posters

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019